Oncology · Medical Literature
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
Abstract
New England Journal of Medicine, Ahead of Print.
Clinical relevance
In men with newly diagnosed high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy, does perioperative (neoadjuvant plus adjuvant) apalutamide added to androgen-deprivation therapy (ADT) improve pathological response and metastasis-free survival compared with perioperative ADT plus placebo? __SNAPSHOT__ {"studyDesign":"Phase 3, randomized, double-blind, placebo-controlled trial with dual co-primary endpoints (PROTEUS; NCT03767244)","setting":"184 sites across 18 countries (international, multicenter); presented at ASCO 2026 and simultaneously published in NEJM (May 31, 2026)","sampleSize":"n = 2,109 (apalutamide + ADT: n = 1,057; placebo + ADT: n = 1,052)","population":"Men with newly diagnosed high-risk localized or locally advanced prostate cancer who were candidates for radical prostatectomy with pelvic lymph-node dissection. Median age 66 years; >95% had Gleason score ≥8; ~40% had baseline PSA ≥20 ng/mL; ~35% had clinical stage ≥T3; ~12% had nodal involvement on conventional imaging. Patients with distant metastatic disease on conventional imaging were excluded. Stratified by nodal status (cN0 vs. N1), Gleason score (7 vs. 8–10), and geographic region.","intervention":"Apalutamide 240 mg orally once daily plus ADT for six 28-day cycles neoadjuvantly (with a 2-week hiatus before surgery), followed by radical prostatectomy with pelvic lymph-node dissection, then six cycles of adjuvant apalutamide plus ADT (total approximately 12 months of systemic therapy)","comparator":"Matched placebo plus ADT administered on the same perioperative schedule","primaryOutcome":"Dual co-primary endpoints, both assessed by blinded independent central review: (1) Pathological complete response or minimal residual disease (pCR/MRD), defined as organ-confined disease (ypT0 or ≤ypT2, N0) with no tumor or residual tumor ≤5 mm in greatest dimension; and (2) Metastasis-free survival (MFS), defined as time to radiographic distant metastasis by conventional imaging or PSMA-PET imaging, histopathologic confirmation of distant metastasis, or death from any cause","followUp":"Median follow-up: 61.7 months (clinical cutoff February 2, 2026)","fundingSource":"Industry (Johnson & Johnson / Janssen)"}
Key findings
The trial met both co-primary endpoints at a median follow-up of 61.7 months. For pCR/MRD: 8.9% of patients in the apalutamide arm achieved pCR/MRD vs. 1.0% in the placebo arm (OR 10.17; 95% CI 5.27–19.64; p<0.0001). Complete tumor eradication (ypT0) occurred in 5.1% vs. 0.4%, respectively. For metastasis-free survival: the 5-year MFS probability was 78.2% (95% CI 75.3–80.8%) in the apalutamide arm vs. 73.5% (95% CI 70.4–76.3%) in the placebo arm, corresponding to a hazard ratio of 0.80 (95% CI 0.67–0.96; p=0.02), representing a 20% relative risk reduction. The absolute difference in 5-year MFS was 4.7 percentage points (calculated). MFS by conventional imaging alone did not reach statistical significance (HR 0.84; 95% CI 0.67–1.07; p=0.15). Key secondary outcomes all favored apalutamide: event-free survival (EFS) was 57.1 months vs. 38.4 months (HR 0.71; 95% CI 0.63–0.80; p<0.001); time to first subsequent local or systemic therapy was 74.2 months vs. 41.5 months (HR 0.65; 95% CI 0.57–0.73; p<0.0001), a difference of ~33 months; time to distant metastasis favored apalutamide (HR 0.68; 95% CI 0.55–0.83; p=0.0002); and time to castration-resistant prostate cancer was also reduced (HR 0.59; 95% CI 0.46–0.76). Exploratory: 17.4% fewer patients in the apalutamide arm required subsequent systemic therapy (26.7% vs. 36.4%) and approximately 30% fewer patients required postoperative radiation. Positive surgical margins were markedly lower in the apalutamide arm (20.9% vs. 42.7%). Overall survival was assessed as an exploratory safety endpoint only; at ~8.5% overall mortality, the HR for death was 1.08—below the prespecified harm threshold but not demonstrating a survival benefit; OS data are immature. NNT for one additional pCR/MRD at surgery: approximately 13 (calculated). NNT to prevent one metastasis or death event at 5 years based on 4.7 percentage-point absolute MFS difference: approximately 21 (calculated). Safety: Grade 3–4 adverse events occurred in 39.6% of the apalutamide arm vs. 31.0% of the placebo arm; the excess was driven primarily by rash. Treatment-related deaths were numerically higher with apalutamide (0.7% vs. 0.1%). Overall treatment discontinuation rates remained low. Testosterone recovery was similar between arms (median ~8.1 months vs. 6.6 months to recovery ≥200 ng/dL).
Practice implications
IMPORTANT LIMITATION: Only the abstract is available for direct review; key quantitative findings cited here are drawn from conference presentations, press releases, and contemporaneous clinical news coverage of the PROTEUS trial, not from independent appraisal of the full manuscript. Clinicians should review the published NEJM article directly before making practice decisions. What the study established: In men with predominantly very high-risk prostate cancer (>95% Gleason ≥8) who are candidates for radical prostatectomy, adding one year of perioperative apalutamide to ADT significantly improved pathological downstaging, metastasis-free survival, event-free survival, and delayed need for subsequent therapy versus perioperative ADT alone, with manageable toxicity and preserved testosterone recovery. What it did not establish: (1) Overall survival benefit—OS data are immature and the point estimate (HR 1.08) does not favor apalutamide at this follow-up; (2) Superiority over surgery alone—the control arm used perioperative ADT, not prostatectomy without systemic therapy, which is the predominant real-world standard; a planned substudy comparing PROTEUS regimen vs. prostatectomy alone (n≈400) has not yet reported; (3) Benefit for patients with only modest high-risk features (e.g., single core of Gleason 8, low-volume disease)—the enrolled population was predominantly very high-risk and the trial investigators themselves cautioned against applying findings to lower-risk patients within the 'high-risk' category; (4) Generalizability to patients ineligible for or unwilling to accept 12 months of ADT/ARPI toxicity burden. The statistically significant MFS benefit rested on a 4.7 percentage-point absolute difference at 5 years, which is modest in absolute terms, though the supporting EFS and time-to-subsequent-therapy data strengthen clinical plausibility. The MFS endpoint was a composite that incorporated PSMA-PET—a more sensitive metastasis-detection modality introduced mid-trial via protocol amendment—potentially inflating the event rate and complicating interpretation. MFS by conventional imaging alone was not statistically significant. The trial was industry-funded by Johnson & Johnson (manufacturer of apalutamide), introducing potential sponsorship bias. The absence of a surgery-alone comparator limits the ability to attribute benefit fully to ARPI intensification vs. any ADT. __LIMITATIONS__ Only abstract available for independent appraisal; full data tables, subgroup analyses, and statistical adjustment details require review of the complete manuscript.,Control arm used perioperative ADT plus placebo—not prostatectomy alone—which is closer to the actual current standard of care for most surgical candidates; this inflates the effective comparator, making apalutamide's incremental benefit over surgery-alone unknown from this trial.,The co-primary MFS endpoint incorporated PSMA-PET imaging (added mid-trial via protocol amendment), a more sensitive modality than conventional imaging; MFS by conventional imaging alone was not statistically significant (HR 0.84; p=0.15), raising questions about endpoint sensitivity and comparability across the enrollment period.,Overall survival is immature (8.5% mortality at median 61.7 months; HR 1.08), assessed only as an exploratory safety endpoint; long-term survival benefit remains unproven.,Industry sponsorship (Johnson & Johnson) introduces risk of reporting bias, endpoint selection bias, and selective emphasis in presentation of results.,Population was predominantly very high-risk (>95% Gleason ≥8, ~40% PSA ≥20 ng/mL, ~12% N1); findings may not apply to patients at the lower end of the 'high-risk' definition.,pCR/MRD rate of 8.9% in the experimental arm, while dramatically better than placebo (1.0%), remains low in absolute terms; the prognostic value of pCR/MRD as a surrogate for long-term OS in localized prostate cancer is not fully validated.,No direct comparison to radiotherapy plus long-term ADT, which is an established alternative standard of care for high-risk localized prostate cancer; comparative effectiveness vs. radiation-based approaches is unknown.,Adverse event excess in the apalutamide arm (Grade 3–4: 39.6% vs. 31.0%), increased treatment-related deaths (0.7% vs. 0.1%), rash burden, and longer testosterone suppression (~8 months to recovery) carry quality-of-life and functional implications not fully quantified in the abstract.,Sequencing implications of early ARPI exposure—particularly future resistance to apalutamide-class agents if metastatic disease eventually develops—were not addressed and represent an unresolved clinical concern. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ The phase 3 PROTEUS trial demonstrated that one year of perioperative apalutamide plus ADT, given around radical prostatectomy in men with very high-risk localized or locally advanced prostate cancer, significantly improved pathological response rates, 5-year metastasis-free survival (78.2% vs. 73.5%; HR 0.80), event-free survival, and delayed subsequent therapy by approximately 33 months compared with perioperative ADT plus placebo. Overall survival benefit remains unproven at current follow-up, the active comparator was perioperative ADT (not surgery alone), and MFS by conventional imaging alone was non-significant—urging careful patient selection and direct review of the full manuscript before adopting this as universal standard of care for all high-risk surgical candidates.